What is NTRB's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.08B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for NTRB?

P/E (TTM) is n/a and 52-week range is $2.80 to $9.19 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s NTRB figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for NTRB?

The company profile lists revenue (TTM) near $2M, net income (TTM) near -$697M, EPS (TTM) near -$0.58 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Nutriband Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Orlando, Florida, US, 12.2M shares outstanding, ISIN US67092M2089 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Nutriband Inc

$NTRB

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. The company is headquartered in Orlando, Florida. The company went IPO on 2017-06-20. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. The company is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Employees

Website

nutriband.com/

IPO

2017-06-20

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US67092M2089

Headquarters

Orlando, Florida, US

Shares outstanding

12.2M

NAICS sector

Manufacturing

Institutional ownership

2.90%

Browse other companiesFree AI scores and summaries for more stocks